149 related articles for article (PubMed ID: 2911781)
1. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
Alberts AS; Falkson G
S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
[TBL] [Abstract][Full Text] [Related]
2. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
3. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
Altman AR; Tschen JA; Rice L
Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
[TBL] [Abstract][Full Text] [Related]
4. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of carcinoid syndrome with a somatostatin analogue].
Döbrönte Z; Stöckert A; Végh G; Varga L
Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
[TBL] [Abstract][Full Text] [Related]
6. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
7. Octreotide treatment of carcinoid hypertensive crisis.
Warner RR; Mani S; Profeta J; Grunstein E
Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity.
Roy RC; Carter RF; Wright PD
Anaesthesia; 1987 Jun; 42(6):627-32. PubMed ID: 2887127
[TBL] [Abstract][Full Text] [Related]
9. [Carcinoid tumor--diagnostic and therapeutic problems].
Batowski S; Bielewicz A
Pol Tyg Lek; 1994 Jun 6-13; 49(23-24):536-7. PubMed ID: 7675710
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment.
Gregor M
Digestion; 1994; 55 Suppl 3():60-3. PubMed ID: 7698539
[TBL] [Abstract][Full Text] [Related]
12. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
[TBL] [Abstract][Full Text] [Related]
13. Migratory thrombophlebitis during sandostatin (SMS 201-995, Sandoz) therapy for malignant carcinoid syndrome.
Nathanson L; Sochet A; Williams ME
Invest New Drugs; 1989 Jul; 7(2-3):285-7. PubMed ID: 2793386
[No Abstract] [Full Text] [Related]
14. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of a patient with carcinoid syndrome with SMS-201-995 (octreotide) for 32 months].
Marcos Sánchez F; Juárez Ucelay F; Plaza Díaz R; García Camba L; Durán Pérez-Navarro A
An Med Interna; 1993 Jun; 10(6):309. PubMed ID: 8334213
[No Abstract] [Full Text] [Related]
16. Successful symptomatic treatment of malignant carcinoid syndrome with the somatostatin analogue SMS 201-995.
van Houten AA; Nortier JW; Vendrik CP
Neth J Med; 1988 Apr; 32(3-4):194-8. PubMed ID: 2896307
[No Abstract] [Full Text] [Related]
17. Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology.
Camisa C
Arch Dermatol; 1989 Mar; 125(3):407-12. PubMed ID: 2564269
[No Abstract] [Full Text] [Related]
18. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
19. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.
Antonelli A; Gambuzza C; Bertoni F; Baschieri L
Clin Ther; 1992; 14(2):178-84. PubMed ID: 1377097
[TBL] [Abstract][Full Text] [Related]
20. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]